Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Income for 6 consecutive years, with -$60.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income rose 28.65% to -$60.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$302.7 million, a 18.72% increase, with the full-year FY2025 number at -$302.7 million, up 18.72% from a year prior.
  • Operating Income was -$60.6 million for Q4 2025 at Relay Therapeutics, up from -$80.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$42.4 million in Q1 2021 to a low of -$193.6 million in Q2 2021.
  • A 5-year average of -$85.6 million and a median of -$82.6 million in 2025 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: plummeted 598.37% in 2021, then skyrocketed 59.8% in 2022.
  • Relay Therapeutics' Operating Income stood at -$67.7 million in 2021, then fell by 7.57% to -$72.9 million in 2022, then dropped by 26.55% to -$92.2 million in 2023, then grew by 7.83% to -$85.0 million in 2024, then grew by 28.65% to -$60.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Operating Income are -$60.6 million (Q4 2025), -$80.4 million (Q3 2025), and -$76.8 million (Q2 2025).